BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/13/2021 10:05:39 AM | Browse: 714 | Download: 1766
 |
Received |
|
2021-01-24 20:49 |
|
Peer-Review Started |
|
2021-01-24 20:53 |
|
First Decision by Editorial Office Director |
|
2021-02-22 06:09 |
|
Return for Revision |
|
2021-02-22 06:09 |
|
Revised |
|
2021-02-22 16:24 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-04-08 12:57 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-04-14 04:17 |
|
Articles in Press |
|
2021-04-14 04:17 |
|
Edit the Manuscript by Language Editor |
|
2021-04-21 03:40 |
|
Typeset the Manuscript |
|
2021-05-12 00:11 |
|
Publish the Manuscript Online |
|
2021-05-13 10:05 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Research & Experimental Medicine |
| Manuscript Type |
Review |
| Article Title |
Receptor for advanced glycation end-products axis and COVID-19 in inflammatory bowel diseases: A dangerous liaison?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Armando Rojas, Iván Schneider, Cristian Lindner, Ileana Gonzàlez and Miguel Angel Morales |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Armando Rojas, PhD, Full Professor, Biomedical Research Labs, Medicine Faculty, Catholic University of Maule, 3605 San Miguel Ave, Talca 3634000, Chile. arojasr@ucm.cl |
| Key Words |
COVID-19; Inflammatory bowel diseases; Advanced glycation; Angiotensin-converting enzyme 2; Alarmins; Receptor for advanced glycation end-products; Receptor for advanced glycation end-products axis; Inflammation |
| Core Tip |
Data raised during the pandemic suggest that inflammatory bowel diseases (IBD) do not have an increased risk of contracting severe acute respiratory syndrome coronavirus 2 infection or develop a more severe course of infection. These findings are in some way unexpected considering that IBD is a chronic inflammatory state of the gastrointestinal tract. We herein discuss how the receptor for advanced glycation end-products (RAGE) axis activation as well as the cross-talk with the renin-angiotensin system are dampened by the high expression of soluble forms of both RAGE and angiotensin-converting enzyme 2. |
| Publish Date |
2021-05-13 10:05 |
| Citation |
Rojas A, Schneider I, Lindner C, Gonzàlez I, Morales MA. Receptor for advanced glycation end-products axis and COVID-19 in inflammatory bowel diseases: A dangerous liaison? World J Gastroenterol 2021; 27(19): 2270-2280 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i19/2270.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i19.2270 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
